ANI Pharmaceuticals (NASDAQ:ANIP) Given New $121.00 Price Target at Guggenheim

ANI Pharmaceuticals (NASDAQ:ANIP) had its price target raised by Guggenheim from $119.00 to $121.00 in a research report released on Friday,Benzinga reports. They currently have a buy rating on the specialty pharmaceutical company’s stock.

ANIP has been the subject of a number of other research reports. Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Oppenheimer initiated coverage on ANI Pharmaceuticals in a research report on Wednesday, September 23rd. They issued a “market perform” rating and a $85.00 target price on the stock. Canaccord Genuity Group cut their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research note on Monday, August 10th. Finally, Leerink Partners started coverage on ANI Pharmaceuticals in a research note on Wednesday, September 9th. They set an “outperform” rating and a $104.00 price target for the company. Three equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $100.00.

ANI Pharmaceuticals Stock Down 3.2%

ANIP stock traded down $2.21 during midday trading on Friday, hitting $67.41. The company’s stock had a trading volume of 578,176 shares, compared to its average volume of 336,812. The company has a market cap of $1.55 billion, a PE ratio of 13.43, a P/E/G ratio of 2.28 and a beta of 0.45. ANI Pharmaceuticals has a 12 month low of $67.14 and a 12 month high of $95.45. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. The firm’s 50-day moving average is $72.52 and its 200-day moving average is $77.32.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.18 by $0.52. The business had revenue of $290.78 million during the quarter, compared to analyst estimates of $280.59 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%. The company’s quarterly revenue was up 27.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.04 EPS. On average, equities research analysts forecast that ANI Pharmaceuticals will post 7.76 earnings per share for the current fiscal year.

Insider Transactions at ANI Pharmaceuticals

In related news, SVP Ori Gutwerg sold 3,162 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $77.00, for a total transaction of $243,474.00. Following the completion of the sale, the senior vice president owned 75,534 shares in the company, valued at approximately $5,816,118. This trade represents a 4.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jeanne Thoma sold 1,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $71.53, for a total value of $71,530.00. Following the sale, the director directly owned 26,762 shares in the company, valued at $1,914,285.86. This trade represents a 3.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 30,412 shares of company stock valued at $2,220,970. 8.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ANIP. Aberdeen Group plc grew its position in shares of ANI Pharmaceuticals by 23.0% during the third quarter. Aberdeen Group plc now owns 334,350 shares of the specialty pharmaceutical company’s stock valued at $24,291,000 after purchasing an additional 62,590 shares in the last quarter. Eurizon Capital SGR S.p.A. bought a new stake in shares of ANI Pharmaceuticals in the third quarter worth about $32,000. Maryland State Retirement & Pension System lifted its position in shares of ANI Pharmaceuticals by 66.4% in the third quarter. Maryland State Retirement & Pension System now owns 4,430 shares of the specialty pharmaceutical company’s stock worth $322,000 after buying an additional 1,768 shares in the last quarter. Illinois Municipal Retirement Fund lifted its position in shares of ANI Pharmaceuticals by 7.2% in the third quarter. Illinois Municipal Retirement Fund now owns 9,719 shares of the specialty pharmaceutical company’s stock worth $706,000 after buying an additional 651 shares in the last quarter. Finally, Penn Capital Management Company LLC lifted its position in shares of ANI Pharmaceuticals by 2.8% in the third quarter. Penn Capital Management Company LLC now owns 213,246 shares of the specialty pharmaceutical company’s stock worth $15,515,000 after buying an additional 5,884 shares in the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI reported Q3 2026 adjusted earnings of $2.70 per share, above the roughly $2.18 analyst consensus, and revenue of $290.78 million versus estimates of $280.59 million. Revenue grew 27.6% year over year, supporting the company’s growth outlook. ANI Q3 financial results
• Positive Sentiment: Guggenheim raised its price target from $119 to $121 and maintained a Buy rating, signaling continued analyst confidence in ANIP’s prospects. Guggenheim ratings
• Neutral Sentiment: ANI announced a recommended offer to acquire Swedish biotech Egetis Therapeutics for SEK 5.6 billion (about $560 million). The deal would expand ANI’s rare-disease business, but its financial impact and execution will matter to investors. ANI offer for Egetis
• Negative Sentiment: The sizable acquisition may raise concerns about funding, integration, and the risks of expanding into a new business, potentially weighing on shares despite the earnings beat. ANI offer to acquire Egetis

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases.